Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 trial of cladribine added to standard therapy in seropositive myasthenia gravis
2020-005762-34Phase 2Active
- Sponsor
- Medical University of Lublin
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of cladribine in myasthenia gravis (MG), sponsored by Medical University of Lublin. Primary endpoint: Change in MG-ADL score. Started Mar 2021; status: active.
02
Drugs
cladribine
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on 2020-005762-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005762-34.